Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga

Eli Lilly and Boehringer Ingelheim's SGLT2 diabetes med Jardiance is chasing at least one holy grail as a treatment for heart failure in patients with or without diabetes—a test AstraZeneca's rival med Farxiga recently aced. But in its first swing at Farxiga's lead, Jardiance whiffed.